BioSyntagma is Granted Patent


bioSyntagma Core Patent for Cancer Research Awarded

Phoenix, AZ — bioSyntagma, LLC announces that it has received a much-needed patent on its foundational technology for the company’s unique microfluidic chip technology, the Light Stream FloCell™, allowing researchers to understand how disease-causing cells interact with each other. bioSyntagma’s technology is seen as fundamental to understanding diseases such as cancer, diabetes, and Alzheimer’s by illuminating key cellular interactions in these disease states. 

The United States Patent and Trademark Office (USPTO) fully issued patent # 15/099,121 for “Method and Apparatus for Extracting and Collecting Single Cells from Formalin-Fixed Paraffin Embedded Tissues,” which bioSyntagma has exclusively licensed from Arizona Technology Enterprises (AzTE), the intellectual property management and technology transfer organization for Arizona State University. 

 “Colleen Ziegler, Dr. Dmitry Derkach, and I are the inventers of this device and founded bioSyntagma based on our ability to provide a level of resolution on tissue samples like patient biopsies down to single cells, which provides insight into serious illnesses like cancer,” said David Richardson, CEO of bioSyntagma. 

"Our technology is positioned to enable doctors and researchers to understand why some people do not respond to cancer treatments, or why some who initially respond become resistant and relapse.  We are thrilled that the USPTO recognized the unique contribution this technology can make,” said Richardson. 

The LightStream FloCell™, or tissue chip, allows scientists, researchers, clinicians, and laboratory technologists to identify single cells, or areas of interests from routine biopsy tissues and move those cells using the tissue chip to a standard collection tube for further analysis.  This capability can help unlock the underlying mechanisms of diseases such as cancer, where differences in cells can cause resistance to even the latest cancer therapies, as well as, diabetes and other autoimmune diseases like arthritis, and neurological disorders like Alzheimer’s.

bioSyntagma is an ASU Venture Devils spinout and a Center for Entrepreneurial Innovation client, located on the GateWay Community College campus.

About bioSyntagma:

bioSyntagma is a resident of the Center for Entrepreneurial Innovation located on the GateWay Community College campus and also a member of the Venture Devils program at Arizona State University.  bioSyntagma has an unmatched capability to extract single and multi-cells from a variety of sample types using a simple, and cost effective, microfluidic tissue chip, the LightStream FloCell™.  The bioSyntagma solution allows cells to be analyzed using advanced technology such as next generation sequencing, and link the resulting information to the spatial location of the sample within the original tissue.  This technology is indispensable for advancing scientific knowledge and the successful clinical treatment of cancer, diabetes, neurological disorders, and auto-immune diseases. The LightStream FloCell™ is a simple, easy to use device that will address workflow issues that prevent the widespread adoption of complex NGS technologies.  For more information on bioSyntagma, visit